Interferon beta in multiple sclerosis.
作者信息
Richards R G
出版信息
BMJ. 1996 Nov 9;313(7066):1159. doi: 10.1136/bmj.313.7066.1159.
Abstract
摘要
相似文献
1
Interferon beta in multiple sclerosis.
BMJ. 1996 Nov 9;313(7066):1159. doi: 10.1136/bmj.313.7066.1159.
2
Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.
BMJ. 1996 Nov 16;313(7067):1263. doi: 10.1136/bmj.313.7067.1263b.
3
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.
BMJ. 1999 Dec 11;319(7224):1529-33. doi: 10.1136/bmj.319.7224.1529.
4
Trial of interferon-beta in multiple sclerosis stopped early.
Lancet. 1998 Feb 21;351(9102):573. doi: 10.1016/S0140-6736(98)23008-X.
5
Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug.
BMJ. 1996 Nov 16;313(7067):1263. doi: 10.1136/bmj.313.7067.1263a.
6
Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
Mult Scler. 1997 Dec;3(6):402. doi: 10.1177/135245859700300610.
7
[Interferon-beta in multiple sclerosis--who is going to be treated?].
Tidsskr Nor Laegeforen. 1999 Sep 10;119(21):3114.
8
The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Arch Neurol. 2001 Aug;58(8):1297-8. doi: 10.1001/archneur.58.8.1297.
9
Beta interferon and multiple sclerosis: why the fuss?
QJM. 1996 Jan;89(1):1-3. doi: 10.1093/oxfordjournals.qjmed.a030132.
10
Treatment of multiple sclerosis with interferon beta-1 b.
Neurology. 1997 Aug;49(2):641-2. doi: 10.1212/wnl.49.2.641.
引用本文的文献
1
Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.
Autoimmune Dis. 2012;2012:784364. doi: 10.1155/2012/784364. Epub 2012 Dec 6.
2
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.
BMJ. 1999 Dec 11;319(7224):1529-33. doi: 10.1136/bmj.319.7224.1529.
3
Linking health technology assessment to practice. Interview by Abi Berger.
BMJ. 1999 Nov 13;319(7220):1292. doi: 10.1136/bmj.319.7220.1292.
4
The need for pharmacoeconomic evaluations in the NHS.
Pharmacoeconomics. 1998 Sep;14(3):241-50. doi: 10.2165/00019053-199814030-00001.
本文引用的文献
1
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Ann Neurol. 1996 Mar;39(3):285-94. doi: 10.1002/ana.410390304.
2
3
4
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Neurology. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268.
5
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
Neurology. 1983 Nov;33(11):1444-52. doi: 10.1212/wnl.33.11.1444.
Zotero 插件